Development of monoclonal antibodies and aptamers anti-troponin I for rapid diagnosis of cardiovascular disease

• Grant number: 14/21698-9
• Support type: Research Grants - Innovative Research in Small Business - PIPE
• Duration: November 01, 2015 - July 31, 2016
• Field of knowledge: Health Sciences - Medicine
• Principal Investigator: Carolina Colombelli Pacca
• Grantee: Carolina Colombelli Pacca
• Company: Dnapta Biotecnologia Ltda (DNAPTA)
• City: São José do Rio Preto

Abstract

The incidence of ischemic heart disease has increased in the world's population currently, which is one of the main causes of mortality. Second World Health Organization (WHO), in 2008, approximately 17 million people died from cardiovascular disease (AD), and more than 80 % of deaths occurred in developing countries. The forecast for 2030 is that more than 30 million people will be affected DC and possibly die .Diagnosis is based on the WHO criteria, where the patient must have characteristic chest pain, electrocardiogram changes diagnostic and elevation of serum biomarkers. The early diagnosis of cardiovascular diseases is of great importance due to the prognosis of the patient to be more effective. Markers of myocardial necrosis are important indicators for the diagnosis, among them the protein troponin I is considered the standard for Acute Myocardial Infarction biochemical analysis. Due to the need for rapid measurement of Troponin I, point of care tests should be developed and implemented to reduce the time of diagnosis and improve the prognosis of the patient. The Immunochromatography lateral flow (Lateral Flow) is a methodology that generates rapid detection and widely used in the world, involving millions of dollars, being used in various fields (medical, veterinary, food). The proposed project for this phase aims to develop lateral flow immunochromatographic assays (Lateral Flow) for the detection of troponin I using specific aptâmeros for protein and monoclonal anti - troponin I. Besides this, the threshold tests are performed detection sensitivity and specificity of tests (ELISA and Lateral Flow commercial) with the recombinant protein in clinical samples of known results .With the success of this proposal will have the basis for the development of electrochemical biosensors, to be requested in Phase 2, to generate a platform for detection. In short , the success of goals and objectives to be achieved with the development of the proposed project , the company will offer the domestic market a rapid detection kit of Troponin I , specific, produced in large more affordable. (AU)